Quote this publication Share Print

JINARC (tolvaptan), vasopressin antagonist

NEPHROLOGY - New medicinal product
Opinions on drugs - Posted on Apr 06 2016

Reason for request

Inclusion

Minor improvement in the treatment of autosomal dominant polycystic kidney disease in adults.

 

  • JINARC has been granted a Marketing Authorisation to slow the progression of the development of cysts and renal failure in autosomal dominant polycystic kidney disease (ADPKD) in adults with stage 1 to 3 chronic kidney disease (CKD) at treatment initiation, with signs of rapid disease progression.
  • It reduces the total kidney volume but does not prevent the growth of cysts or cause their decrease. When the treatment is stopped, growth of the renal cysts resumes. Chronic treatment with tolvaptan is thus required even if the safety of an elevated cumulative dose is unknown.
  • Its use should be limited only to adults with confirmed (Pei-modified Ravine criteria, family history or genetic testing), progressive ADPKD at risk of unfavourable progression of renal function.
  • There are still uncertainties regarding the long-term hepatic safety and the consequences of combination with medicinal products that block the renin-angiotensin system.

Actual benefit

Modéré

-


Improvement in actual benefit

IV (mineur)

-


Therapeutic use

-

Contact Us

Évaluation des médicaments